Paratek & Project BioShield
Off the Shelf · Federal News Network | Hubbard Radio
Audio is streamed directly from the publisher (mgln.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This week Dr. Evan Loh, Paratek CEO, returns to Off the
Shelf to share the latest in the biopharmaceutical company’s partnership with
the Biomedical Advanced Research and Development Authority’s (BARDA’s)
Project BioShield.
Paratek’s antibiotic, NUZYRA (omadacycline) has been
designated “an essential” medicine by the FDA, and Loh provides an update
on the progress made in onshoring of manufacturing of NUZYRA, from the
production of API through finished drug product for both IV and oral
formulations.
Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek’s public-private partnership with BARDA played in developing manufacturing capability.
Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations in
combatting these and other healthcare threats.
Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protect
the warfighter.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.